NCT03857178|Completed
SABINA INTERNATIONAL
A Multi-country Study on the Prescription Patterns of Short Acting Beta-2 Agonist (SABA) and Its Potential Effects on Asthma Control: A Cross-Sectional Study on SABA Use in Asthma
Loading search results
A Multi-country Study on the Prescription Patterns of Short Acting Beta-2 Agonist (SABA) and Its Potential Effects on Asthma Control: A Cross-Sectional Study on SABA Use in Asthma
Sponsor study identifier
observational
8,617
1 country
1
Study Start
March 29, 2019
Actual (reported)Primary Completion
May 6, 2020
Actual (reported)Study Completion
May 6, 2020
Actual (reported)The aim of the study is to describe the prescribing pattern of the different types of medications which are used to treat asthma, across multiple countries.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 6, 2020
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 25, 2019
Actual (reported)February 27, 2019
Actual (reported)March 29, 2019
Actual (reported)May 6, 2020
Actual (reported)May 6, 2020
Actual (reported)The main outcome will be a categorisation of SABA prescription in asthma patients.
Mild asthma patients will be categorised into 5 groups according to the number of SABA and ICS prescriptions in the 12 months prior to their index date (initial exposure window): 1. No prescriptions for asthma inhalers 2. Appropriate SABA prescription with no ICS 3. Appropriate SABA prescription with ICS 4. SABA over-prescription with no ICS 5. SABA over-prescription with ICS Moderate/severe asthma patients will be categorised into 2 groups according to the number of SABA and ICS prescriptions in the 12 months prior to their index date: 1. Appropriate SABA prescription on top of maintenance therapy 2. SABA over-prescription on top of maintenance therapy
12 months retrospective from index date
The selection of sites and investigators will be made with the aim to achieve representativeness in the way asthma is managed in each participating country. The study will include patients from either primary care centres, or specialist centres involved in the management of asthma, or a mix of both within a country to ensure representativeness.
Research Site
San Salvador, Argentina
Tan DHY, Tan TL, Tan WH, Choong C, Beekman MJHI, Khor JH, Kumar SS, Wong GR, Lim HF. SABA prescriptions and asthma management practices in Singapore: results from a cross-sectional, observational SABINA III study. BMJ Open. 2024 Jun 10;14(6):e064245. doi: 10.1136/bmjopen-2022-064245.
Alzaabi A, Al Busaidi N, Pradhan R, Shandy F, Ibrahim N, Ashtar M, Khudadah K, Hegazy K, Samir M, Negm M, Farouk H, Al Khalidi A, Beekman M. Over-prescription of short-acting beta2-agonists and asthma management in the Gulf region: a multicountry observational study. Asthma Res Pract. 2022 Jul 7;8(1):3. doi: 10.1186/s40733-022-00085-5.
8,617 participants (actual enrollment reported by the registry).
First Submitted
February 25, 2019
First Posted
February 27, 2019
Study Start
March 29, 2019
Actual (reported)Contact the study team to confirm eligibility.
Bateman ED, Price DB, Wang HC, Khattab A, Schonffeldt P, Catanzariti A, van der Valk RJP, Beekman MJHI. Short-acting beta2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. Eur Respir J. 2022 May 5;59(5):2101402. doi: 10.1183/13993003.01402-2021. Print 2022 May.
Primary Completion
May 6, 2020
Actual (reported)Study Completion
May 6, 2020
Actual (reported)Last Updated
February 11, 2021
Record last verified: 2021-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: